Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Antidiabetic Biguanides market report explains the definition, types, applications, major countries, and major players of the Antidiabetic Biguanides market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
GlaxoSmithKline
Merck & Co
AstraZeneca
Bristol-Myers Squibb
Novo Nordisk
Takeda Pharmaceuticals
Boehringer Ingelheim
Eli Lilly
Sanofi
Servier Laboratories
Pfizer
By Type:
Metformin IR
Metformin SR
By End-User:
Hospitals
Clinics
Other
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Antidiabetic Biguanides Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Antidiabetic Biguanides Outlook to 2028- Original Forecasts
-
2.2 Antidiabetic Biguanides Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Antidiabetic Biguanides Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Antidiabetic Biguanides Market- Recent Developments
-
6.1 Antidiabetic Biguanides Market News and Developments
-
6.2 Antidiabetic Biguanides Market Deals Landscape
7 Antidiabetic Biguanides Raw Materials and Cost Structure Analysis
-
7.1 Antidiabetic Biguanides Key Raw Materials
-
7.2 Antidiabetic Biguanides Price Trend of Key Raw Materials
-
7.3 Antidiabetic Biguanides Key Suppliers of Raw Materials
-
7.4 Antidiabetic Biguanides Market Concentration Rate of Raw Materials
-
7.5 Antidiabetic Biguanides Cost Structure Analysis
-
7.5.1 Antidiabetic Biguanides Raw Materials Analysis
-
7.5.2 Antidiabetic Biguanides Labor Cost Analysis
-
7.5.3 Antidiabetic Biguanides Manufacturing Expenses Analysis
8 Global Antidiabetic Biguanides Import and Export Analysis (Top 10 Countries)
-
8.1 Global Antidiabetic Biguanides Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Antidiabetic Biguanides Export by Region (Top 10 Countries) (2017-2028)
9 Global Antidiabetic Biguanides Market Outlook by Types and Applications to 2022
-
9.1 Global Antidiabetic Biguanides Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Metformin IR Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Metformin SR Consumption and Growth Rate (2017-2022)
-
9.2 Global Antidiabetic Biguanides Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Other Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Antidiabetic Biguanides Market Analysis and Outlook till 2022
-
10.1 Global Antidiabetic Biguanides Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Antidiabetic Biguanides Consumption (2017-2022)
-
10.2.2 Canada Antidiabetic Biguanides Consumption (2017-2022)
-
10.2.3 Mexico Antidiabetic Biguanides Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.2 UK Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.3 Spain Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.4 Belgium Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.5 France Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.6 Italy Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.7 Denmark Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.8 Finland Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.9 Norway Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.10 Sweden Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.11 Poland Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.12 Russia Antidiabetic Biguanides Consumption (2017-2022)
-
10.3.13 Turkey Antidiabetic Biguanides Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.2 Japan Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.3 India Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.4 South Korea Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.5 Pakistan Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.6 Bangladesh Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.7 Indonesia Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.8 Thailand Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.9 Singapore Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.10 Malaysia Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.11 Philippines Antidiabetic Biguanides Consumption (2017-2022)
-
10.4.12 Vietnam Antidiabetic Biguanides Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Antidiabetic Biguanides Consumption (2017-2022)
-
10.5.2 Colombia Antidiabetic Biguanides Consumption (2017-2022)
-
10.5.3 Chile Antidiabetic Biguanides Consumption (2017-2022)
-
10.5.4 Argentina Antidiabetic Biguanides Consumption (2017-2022)
-
10.5.5 Venezuela Antidiabetic Biguanides Consumption (2017-2022)
-
10.5.6 Peru Antidiabetic Biguanides Consumption (2017-2022)
-
10.5.7 Puerto Rico Antidiabetic Biguanides Consumption (2017-2022)
-
10.5.8 Ecuador Antidiabetic Biguanides Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Antidiabetic Biguanides Consumption (2017-2022)
-
10.6.2 Kuwait Antidiabetic Biguanides Consumption (2017-2022)
-
10.6.3 Oman Antidiabetic Biguanides Consumption (2017-2022)
-
10.6.4 Qatar Antidiabetic Biguanides Consumption (2017-2022)
-
10.6.5 Saudi Arabia Antidiabetic Biguanides Consumption (2017-2022)
-
10.6.6 United Arab Emirates Antidiabetic Biguanides Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Antidiabetic Biguanides Consumption (2017-2022)
-
10.7.2 South Africa Antidiabetic Biguanides Consumption (2017-2022)
-
10.7.3 Egypt Antidiabetic Biguanides Consumption (2017-2022)
-
10.7.4 Algeria Antidiabetic Biguanides Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Antidiabetic Biguanides Consumption (2017-2022)
-
10.8.2 New Zealand Antidiabetic Biguanides Consumption (2017-2022)
11 Global Antidiabetic Biguanides Competitive Analysis
-
11.1 GlaxoSmithKline
-
11.1.1 GlaxoSmithKline Company Details
-
11.1.2 GlaxoSmithKline Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 GlaxoSmithKline Antidiabetic Biguanides Main Business and Markets Served
-
11.1.4 GlaxoSmithKline Antidiabetic Biguanides Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Merck & Co
-
11.2.1 Merck & Co Company Details
-
11.2.2 Merck & Co Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Merck & Co Antidiabetic Biguanides Main Business and Markets Served
-
11.2.4 Merck & Co Antidiabetic Biguanides Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 AstraZeneca
-
11.3.1 AstraZeneca Company Details
-
11.3.2 AstraZeneca Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 AstraZeneca Antidiabetic Biguanides Main Business and Markets Served
-
11.3.4 AstraZeneca Antidiabetic Biguanides Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Bristol-Myers Squibb
-
11.4.1 Bristol-Myers Squibb Company Details
-
11.4.2 Bristol-Myers Squibb Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Bristol-Myers Squibb Antidiabetic Biguanides Main Business and Markets Served
-
11.4.4 Bristol-Myers Squibb Antidiabetic Biguanides Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Novo Nordisk
-
11.5.1 Novo Nordisk Company Details
-
11.5.2 Novo Nordisk Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Novo Nordisk Antidiabetic Biguanides Main Business and Markets Served
-
11.5.4 Novo Nordisk Antidiabetic Biguanides Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Takeda Pharmaceuticals
-
11.6.1 Takeda Pharmaceuticals Company Details
-
11.6.2 Takeda Pharmaceuticals Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Takeda Pharmaceuticals Antidiabetic Biguanides Main Business and Markets Served
-
11.6.4 Takeda Pharmaceuticals Antidiabetic Biguanides Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Boehringer Ingelheim
-
11.7.1 Boehringer Ingelheim Company Details
-
11.7.2 Boehringer Ingelheim Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Boehringer Ingelheim Antidiabetic Biguanides Main Business and Markets Served
-
11.7.4 Boehringer Ingelheim Antidiabetic Biguanides Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Eli Lilly
-
11.8.1 Eli Lilly Company Details
-
11.8.2 Eli Lilly Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Eli Lilly Antidiabetic Biguanides Main Business and Markets Served
-
11.8.4 Eli Lilly Antidiabetic Biguanides Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Sanofi
-
11.9.1 Sanofi Company Details
-
11.9.2 Sanofi Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Sanofi Antidiabetic Biguanides Main Business and Markets Served
-
11.9.4 Sanofi Antidiabetic Biguanides Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Servier Laboratories
-
11.10.1 Servier Laboratories Company Details
-
11.10.2 Servier Laboratories Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Servier Laboratories Antidiabetic Biguanides Main Business and Markets Served
-
11.10.4 Servier Laboratories Antidiabetic Biguanides Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Pfizer
-
11.11.1 Pfizer Company Details
-
11.11.2 Pfizer Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Pfizer Antidiabetic Biguanides Main Business and Markets Served
-
11.11.4 Pfizer Antidiabetic Biguanides Product Portfolio
-
11.11.5 Recent Research and Development Strategies
12 Global Antidiabetic Biguanides Market Outlook by Types and Applications to 2028
-
12.1 Global Antidiabetic Biguanides Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Metformin IR Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Metformin SR Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Antidiabetic Biguanides Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Antidiabetic Biguanides Market Analysis and Outlook to 2028
-
13.1 Global Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.2.2 Canada Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.2.3 Mexico Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.2 UK Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.3 Spain Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.4 Belgium Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.5 France Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.6 Italy Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.7 Denmark Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.8 Finland Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.9 Norway Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.10 Sweden Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.11 Poland Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.12 Russia Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.3.13 Turkey Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.2 Japan Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.3 India Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.4 South Korea Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.8 Thailand Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.9 Singapore Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.11 Philippines Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.5.2 Colombia Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.5.3 Chile Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.5.4 Argentina Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.5.6 Peru Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.6.3 Oman Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.6.4 Qatar Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.7.2 South Africa Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.7.3 Egypt Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.7.4 Algeria Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Antidiabetic Biguanides Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Antidiabetic Biguanides Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Antidiabetic Biguanides
-
Figure of Antidiabetic Biguanides Picture
-
Table Global Antidiabetic Biguanides Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Antidiabetic Biguanides Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Metformin IR Consumption and Growth Rate (2017-2022)
-
Figure Global Metformin SR Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Antidiabetic Biguanides Consumption by Country (2017-2022)
-
Table North America Antidiabetic Biguanides Consumption by Country (2017-2022)
-
Figure United States Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Canada Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Mexico Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Table Europe Antidiabetic Biguanides Consumption by Country (2017-2022)
-
Figure Germany Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure UK Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Spain Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Belgium Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure France Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Italy Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Denmark Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Finland Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Norway Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Sweden Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Poland Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Russia Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Turkey Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Table APAC Antidiabetic Biguanides Consumption by Country (2017-2022)
-
Figure China Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Japan Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure India Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure South Korea Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Thailand Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Singapore Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Philippines Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Table South America Antidiabetic Biguanides Consumption by Country (2017-2022)
-
Figure Brazil Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Colombia Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Chile Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Argentina Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Peru Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Table GCC Antidiabetic Biguanides Consumption by Country (2017-2022)
-
Figure Bahrain Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Oman Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Qatar Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Table Africa Antidiabetic Biguanides Consumption by Country (2017-2022)
-
Figure Nigeria Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure South Africa Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Egypt Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure Algeria Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Table Oceania Antidiabetic Biguanides Consumption by Country (2017-2022)
-
Figure Australia Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Antidiabetic Biguanides Consumption and Growth Rate (2017-2022)
-
Table GlaxoSmithKline Company Details
-
Table GlaxoSmithKline Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Antidiabetic Biguanides Main Business and Markets Served
-
Table GlaxoSmithKline Antidiabetic Biguanides Product Portfolio
-
Table Merck & Co Company Details
-
Table Merck & Co Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck & Co Antidiabetic Biguanides Main Business and Markets Served
-
Table Merck & Co Antidiabetic Biguanides Product Portfolio
-
Table AstraZeneca Company Details
-
Table AstraZeneca Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Antidiabetic Biguanides Main Business and Markets Served
-
Table AstraZeneca Antidiabetic Biguanides Product Portfolio
-
Table Bristol-Myers Squibb Company Details
-
Table Bristol-Myers Squibb Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Antidiabetic Biguanides Main Business and Markets Served
-
Table Bristol-Myers Squibb Antidiabetic Biguanides Product Portfolio
-
Table Novo Nordisk Company Details
-
Table Novo Nordisk Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novo Nordisk Antidiabetic Biguanides Main Business and Markets Served
-
Table Novo Nordisk Antidiabetic Biguanides Product Portfolio
-
Table Takeda Pharmaceuticals Company Details
-
Table Takeda Pharmaceuticals Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Pharmaceuticals Antidiabetic Biguanides Main Business and Markets Served
-
Table Takeda Pharmaceuticals Antidiabetic Biguanides Product Portfolio
-
Table Boehringer Ingelheim Company Details
-
Table Boehringer Ingelheim Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Antidiabetic Biguanides Main Business and Markets Served
-
Table Boehringer Ingelheim Antidiabetic Biguanides Product Portfolio
-
Table Eli Lilly Company Details
-
Table Eli Lilly Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Antidiabetic Biguanides Main Business and Markets Served
-
Table Eli Lilly Antidiabetic Biguanides Product Portfolio
-
Table Sanofi Company Details
-
Table Sanofi Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Antidiabetic Biguanides Main Business and Markets Served
-
Table Sanofi Antidiabetic Biguanides Product Portfolio
-
Table Servier Laboratories Company Details
-
Table Servier Laboratories Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table Servier Laboratories Antidiabetic Biguanides Main Business and Markets Served
-
Table Servier Laboratories Antidiabetic Biguanides Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Antidiabetic Biguanides Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Antidiabetic Biguanides Main Business and Markets Served
-
Table Pfizer Antidiabetic Biguanides Product Portfolio
-
Figure Global Metformin IR Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Metformin SR Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Antidiabetic Biguanides Consumption Forecast by Country (2022-2028)
-
Table North America Antidiabetic Biguanides Consumption Forecast by Country (2022-2028)
-
Figure United States Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Antidiabetic Biguanides Consumption Forecast by Country (2022-2028)
-
Figure Germany Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Antidiabetic Biguanides Consumption Forecast by Country (2022-2028)
-
Figure China Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Antidiabetic Biguanides Consumption Forecast by Country (2022-2028)
-
Figure Brazil Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Antidiabetic Biguanides Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Antidiabetic Biguanides Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Antidiabetic Biguanides Consumption Forecast by Country (2022-2028)
-
Figure Australia Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Antidiabetic Biguanides Consumption Forecast and Growth Rate (2022-2028)
-
